Kyowa Kirin Pharmaceutical Development Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.kyowakirin.com
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
Phase 1
Completed
- Conditions
- Chemotherapy Induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Target Recruit Count
- 19
- Registration Number
- NCT01596400
- Locations
- 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸Nemours Children's Clinic, Jacksonville, Florida, United States
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years
Phase 1
Withdrawn
- Conditions
- Chemotherapy Induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Registration Number
- NCT01596426
Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years
Phase 1
Withdrawn
- Conditions
- Chemotherapy Induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Registration Number
- NCT01596413
© Copyright 2025. All Rights Reserved by MedPath